Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference. The presentation will take place at 11am Eastern time on 27 September 2023.

Dexcom Canada and RxFood Corporation Partner on AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management

Dexcom, Inc., a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, and RxFood Corporation, the leader in AI-driven personalized nutrition assessments, announced today their partnership in Canada to introduce an improved digital health solution for those living with diabetes. Within the RxFood app, Dexcom CGM users can capture photos of their meals, eliminating the need for manual food and nutrition tracking. As they photo-log their food, RxFood will continuously generate detailed diet quality metrics that are combined with glucose data, making it easily accessible to both patients and their dedicated clinicians. The combination of RxFood with Dexcom CGM addresses the need for unified, time-matched food and glucose data reports to effectively manage diabetes and enable personalized nutritional guidance at scale.

Kakao Healthcare, i-SENS to enhance diabetes care through CGM, digital health services

Kakao Healthcare and i-SENS said they have signed a contract to cooperate in the supply of continuous glucose monitoring (CGM) devices and data linkage-based blood glucose management services. The two companies have been discussing cooperation since July last year and had signed a memorandum of understanding for cooperation in the chronic disease management business in January this year. Under the accord, the two companies plan to provide innovative digital healthcare services by combining Kakao Healthcare's platform and artificial intelligence capabilities with i-SENS's biosensor expertise, including CGM devices. Also, i-SENS will supply its CGM device, CareSens Air, to Kakao Healthcare, which will then distribute the product through its platform.

Beta Bionics Secures $100 Million in Series D Funding to Advance Diabetes Technology and Expand Market Presence

Beta Bionics, Inc. is thrilled to announce the successful closure of its Series D funding round securing $100 million in new equity capital. The Series D funding was co-led by new investors Sands Capital and Omega Funds with an additional new investor, Marshall Wace, also participating. Previous investors Soleus Capital, Eventide Asset Management LLC, Farallon Capital, Perceptive Advisors, certain funds managed by RTW Investments, LP, ArrowMark Partners, and Pura Vida Investments also participated.

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany

DexCom, Inc., global manufacturer of systems for real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) is the first and only CGM to connect to the Omnipod 5 AID System in Germany, helping users to protect against high and low glucose levels. “At Dexcom we believe that diabetes technology should be built to celebrate and support the diabetes community. This launch gives Dexcom users in Germany another choice in automated insulin delivery systems, adding to the company’s existing insulin delivery collaborations with Tandem, Ypsomed and CamDiab. We are delighted to see years of close collaboration with industry partners result in giving people with diabetes unparalleled choice, peace of mind and better clinical outcomes,” said Alexander Fröhlich, Vice President for Germany, Austria, Switzerland, and Slovenia at Dexcom.

The Froedtert & the Medical College of Wisconsin Health Network Leverages Digital Health to Engage High Risk Employees in Maintaining a Healthy Weight

Xealth today announced that The Froedtert & the Medical College of Wisconsin health network is leveraging its digital health platform to engage select employees into the Omada Health virtual care program. Xealth facilitates communication outreach, which comes from The Froedtert & MCW health network, and offers deeper insight into program enrollment and engagement. Omada is the 10th digital health app that the health system has added to this platform, which covers a variety of clinical areas, including mental health, maternity, diabetes and others.

ABBOTT AND WEIGHTWATCHERS CONNECTED APP EXPERIENCE IS NOW AVAILABLE FOR PEOPLE LIVING WITH DIABETES

Abbott and WW International, Inc., known as WeightWatchers, announced today the availability of a connected app to help people living with diabetes understand how food and activity impact their glucose levels. WeightWatchers members who follow the WW Diabetes-Tailored Plan can now access their glucose data from Abbott's FreeStyle Libre 2, a continuous glucose monitoring (CGM) system, within their WW app while being guided by the WW Diabetes-Tailored Plan. From now until Dec. 31, 2023, new WW members can enjoy a free month of the WeightWatchers Diabetes-Tailored Plan and connect the WW app with the FreeStyle Libre 2 system. Any new FreeStyle Libre 2 users may be eligible to receive a voucher for a free trial of the FreeStyle Libre 2 system when they sign up for the MyFreeStyle Libre program.

ABBOTT TO ACQUIRE BIGFOOT BIOMEDICAL, FURTHERING EFFORTS TO DEVELOP PERSONALIZED, CONNECTED SOLUTIONS FOR PEOPLE WITH DIABETES

Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2023. Financial terms were not disclosed. 

Abbott and Bigfoot have worked together on connected diabetes solutions since 2017. Bigfoot developed Bigfoot Unity®, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data along with healthcare provider instructions to provide insulin dosing recommendations. The dosing recommendations are displayed on the pen cap's digital screen to help people know how much insulin to take. The Bigfoot Unity system exclusively works with Abbott's world-leading FreeStyle Libre® technology and includes a customer smartphone app connected to a cloud-based online portal used by healthcare providers to support their patients, including through remote care.

Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase

Senseonics Holdings today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Management is scheduled to present on Thursday, September 21, 2023 from 11:30 a.m. to 11:55 a.m. ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million loan facility with Hercules Capital, Inc. The company also announced it drew down $25 million upon the transaction closing.